Illumina, Inc. (NASDAQ:ILMN) Director Robert S. Epstein sold 1,250 shares of the company’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $217.38, for a total transaction of $271,725.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Illumina, Inc. (NASDAQ:ILMN) opened at $232.99 on Friday. The stock has a market cap of $34,020.00, a P/E ratio of 43.96, a P/E/G ratio of 3.15 and a beta of 0.79. Illumina, Inc. has a fifty-two week low of $132.02 and a fifty-two week high of $233.54. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. The business had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the business earned $0.97 EPS. equities analysts expect that Illumina, Inc. will post 3.75 earnings per share for the current year.
A number of equities research analysts have issued reports on the stock. BTIG Research assumed coverage on shares of Illumina in a research note on Friday. They set a “hold” rating on the stock. Piper Jaffray Companies increased their price objective on shares of Illumina to $274.00 and gave the stock an “overweight” rating in a research note on Thursday. Evercore ISI assumed coverage on shares of Illumina in a research note on Wednesday. They set an “outperform” rating and a $250.00 price objective on the stock. Wells Fargo & Co upgraded shares of Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price objective on the stock in a research note on Tuesday. Finally, Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $207.74.
A number of hedge funds and other institutional investors have recently modified their holdings of ILMN. Winslow Capital Management LLC bought a new position in Illumina in the 2nd quarter valued at approximately $211,584,000. HPM Partners LLC raised its holdings in Illumina by 29,103.8% in the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after buying an additional 749,424 shares during the last quarter. Fred Alger Management Inc. raised its holdings in Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after buying an additional 548,030 shares during the last quarter. TIAA CREF Investment Management LLC raised its holdings in Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares during the last quarter. Finally, Capital World Investors raised its holdings in Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares during the last quarter. Institutional investors and hedge funds own 91.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Insider Selling: Illumina, Inc. (ILMN) Director Sells $271,725.00 in Stock” was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://transcriptdaily.com/2018/01/05/insider-selling-illumina-inc-ilmn-director-sells-271725-00-in-stock.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.